• Je něco špatně v tomto záznamu ?

COVID-19 vaccination and relapse activity: A nationwide cohort study of patients with multiple sclerosis in Denmark

D. Stastna, F. Elberling, L. Pontieri, E. Framke, D. Horakova, J. Drahota, P. Nytrova, M. Magyari

. 2024 ; 31 (3) : e16163. [pub] 20231128

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24006972

Grantová podpora
Agentura Pro Zdravotnický Výzkum České Republiky
European Union - Next Generation EU
Ministerstvo Zdravotnictví Ceské Republiky
Univerzita Karlova v Praze

BACKGROUND AND PURPOSE: We evaluated whether there was a difference in the occurrence of relapses pre- and post-COVID-19 vaccination in a nationwide cohort of Danish patients with relapsing multiple sclerosis. METHODS: We conducted a population-based, nationwide cohort study with a cutoff date of 1 October 2022. We used McNemar tests to assess changes in the proportion of patients with recorded relapses within 90 days and 180 days before and after first vaccine dose, and a negative binomial regression model to compare the 90 and 180 days postvaccination annualized relapse rate (ARR) to the 360 days prevaccination ARR. Multivariate Cox regression was used to estimate relapse risk factors. RESULTS: We identified 8169 vaccinated (87.3% Comirnaty) patients without a recorded history of a positive COVID-19 test. We did not find statistically significant changes in the proportion of patients with relapses in the 90 days (1.3% vs. 1.4% of patients, p = 0.627) and 180 days (2.7% vs. 2.6% of patients, p = 0.918) pre- and postvaccination. Also, a comparison of the ARR 360 days before (0.064, 95% confidence interval [CI] = 0.058-0.070) with the ARR 90 (0.057, 95% CI = 0.047-0.069, p = 0.285) and 180 (0.055, 95% CI = 0.048-0.063, p = 0.060) days after vaccination did not show statistically significant differences. Lower age, higher Expanded Disability Status Scale score, and relapse within 360 days before vaccination were associated with a higher risk of relapse. CONCLUSIONS: We did not find evidence of increased relapse activity following the administration of the first dose of the COVID-19 vaccine.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24006972
003      
CZ-PrNML
005      
20240423155621.0
007      
ta
008      
240412s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/ene.16163 $2 doi
035    __
$a (PubMed)38015454
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Stastna, Dominika $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia $u Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital-Rigshospitalet, Glostrup, Denmark $1 https://orcid.org/0000000324184847
245    10
$a COVID-19 vaccination and relapse activity: A nationwide cohort study of patients with multiple sclerosis in Denmark / $c D. Stastna, F. Elberling, L. Pontieri, E. Framke, D. Horakova, J. Drahota, P. Nytrova, M. Magyari
520    9_
$a BACKGROUND AND PURPOSE: We evaluated whether there was a difference in the occurrence of relapses pre- and post-COVID-19 vaccination in a nationwide cohort of Danish patients with relapsing multiple sclerosis. METHODS: We conducted a population-based, nationwide cohort study with a cutoff date of 1 October 2022. We used McNemar tests to assess changes in the proportion of patients with recorded relapses within 90 days and 180 days before and after first vaccine dose, and a negative binomial regression model to compare the 90 and 180 days postvaccination annualized relapse rate (ARR) to the 360 days prevaccination ARR. Multivariate Cox regression was used to estimate relapse risk factors. RESULTS: We identified 8169 vaccinated (87.3% Comirnaty) patients without a recorded history of a positive COVID-19 test. We did not find statistically significant changes in the proportion of patients with relapses in the 90 days (1.3% vs. 1.4% of patients, p = 0.627) and 180 days (2.7% vs. 2.6% of patients, p = 0.918) pre- and postvaccination. Also, a comparison of the ARR 360 days before (0.064, 95% confidence interval [CI] = 0.058-0.070) with the ARR 90 (0.057, 95% CI = 0.047-0.069, p = 0.285) and 180 (0.055, 95% CI = 0.048-0.063, p = 0.060) days after vaccination did not show statistically significant differences. Lower age, higher Expanded Disability Status Scale score, and relapse within 360 days before vaccination were associated with a higher risk of relapse. CONCLUSIONS: We did not find evidence of increased relapse activity following the administration of the first dose of the COVID-19 vaccine.
650    _2
$a lidé $7 D006801
650    12
$a roztroušená skleróza $7 D009103
650    _2
$a kohortové studie $7 D015331
650    _2
$a vakcíny proti COVID-19 $x terapeutické užití $7 D000086663
650    12
$a relabující-remitující roztroušená skleróza $7 D020529
650    12
$a COVID-19 $x prevence a kontrola $7 D000086382
650    _2
$a chronická nemoc $7 D002908
650    _2
$a recidiva $7 D012008
650    _2
$a vakcinace $7 D014611
651    _2
$a Dánsko $x epidemiologie $7 D003718
655    _2
$a časopisecké články $7 D016428
700    1_
$a Elberling, Frederik $u Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital-Rigshospitalet, Glostrup, Denmark
700    1_
$a Pontieri, Luigi $u Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital-Rigshospitalet, Glostrup, Denmark $1 https://orcid.org/0000000215063827
700    1_
$a Framke, Elisabeth $u Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital-Rigshospitalet, Glostrup, Denmark
700    1_
$a Horakova, Dana $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia $1 https://orcid.org/0000000319150036
700    1_
$a Drahota, Jiri $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia $u Endowment Fund IMPULS, Prague, Czechia $1 https://orcid.org/0000000334162094
700    1_
$a Nytrova, Petra $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia $1 https://orcid.org/000000034885602X $7 xx0107120
700    1_
$a Magyari, Melinda $u Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital-Rigshospitalet, Glostrup, Denmark $u Danish Multiple Sclerosis Centre, Department of Neurology, Copenhagen University Hospital-Rigshospitalet, Glostrup, Denmark $u Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark $1 https://orcid.org/0000000209725222
773    0_
$w MED00001629 $t European journal of neurology $x 1468-1331 $g Roč. 31, č. 3 (2024), s. e16163
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38015454 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155618 $b ABA008
999    __
$a ok $b bmc $g 2081137 $s 1216739
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 31 $c 3 $d e16163 $e 20231128 $i 1468-1331 $m European journal of neurology $n Eur J Neurol $x MED00001629
GRA    __
$p Agentura Pro Zdravotnický Výzkum České Republiky
GRA    __
$p European Union - Next Generation EU
GRA    __
$p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$p Univerzita Karlova v Praze
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace